Immunovant Inc (IMVT) — Cash Flow-to-Debt Ratio
Latest as of December 2025:
-1.39x
Immunovant Inc (IMVT) has a Cash Flow-to-Debt Ratio of -1.39x as of December 2025, meaning its operating cash flow of $-92.33 Million could theoretically repay -1% of its total liabilities ($66.26 Million) in one year. Check Immunovant Inc (IMVT) cash flow quality to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
-1.39x
Operating CF / Total Liabilities
Operating Cash Flow
$-92.33 Million
USD
Total Liabilities
$66.26 Million
USD
Data as of
Dec 2025
Most recent filing
Immunovant Inc Cash Flow-to-Debt Ratio (2018–2025)
Historical debt coverage capacity for Immunovant Inc across 8 annual periods. Also explore IMVT asset base for the complete picture of this company's asset base.
Annual Cash Flow-to-Debt Ratio for Immunovant Inc (2018–2025)
Year-by-year debt coverage analysis for Immunovant Inc. For market capitalisation and broader financial context, see IMVT market cap.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -5.47x | $-375.87 Million | $68.78 Million | ▼ -24.9% |
| 2024 | -4.38x | $-214.23 Million | $48.95 Million | ▼ -0.8% |
| 2023 | -4.34x | $-188.19 Million | $43.34 Million | ▼ -87.2% |
| 2022 | -2.32x | $-106.11 Million | $45.74 Million | ▲ +41.5% |
| 2021 | -3.97x | $-83.33 Million | $21.01 Million | ▼ -13.9% |
| 2020 | -3.48x | $-53.36 Million | $15.32 Million | ▲ +95.4% |
| 2019 | -75.04x | $-28.55 Million | $380.45K | ▲ +5.8% |
| 2018 | -79.69x | $-128.30 Million | $1.61 Million | — |
Cash Flow-to-Debt Ratio = Operating Cash Flow / Total Liabilities. Higher is better for debt service capacity.